Condition
Scleroderma Spectrum of Diseases
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Tadalafil And Ambrisentan Upfront Combination Therapy
Research Leaders
8 sponsors active, led by National Heart, Lung, and Blood Institute (NHLBI)
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Phase 4 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Tadalafil And Ambrisentan Upfront Combination Therapy1
Active Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)1
- University of Texas1
- Johns Hopkins University1
- National Institutes of Health (NIH)1
- United Therapeutics1
Top Investigators
Johns Hopkins University
Related Conditions
- Pulmonary Arterial Hypertension1
- Connective Tissue Disease1
- Pulmonary Hypertension1
- Systemic Sclerosis1